Drugs & Therapy Perspectives

, Volume 35, Issue 4, pp 167–170 | Cite as

Manage endometriosis-related pain with hormonal suppression therapies

  • Adis Medical WritersEmail author
Disease Management


Endometriosis is a benign chronic inflammatory disease that mostly affects women of reproductive age. The disease is often associated with dysmenorrhoea, pelvic and non-menstrual pain, and infertility. NSAIDs and hormonal suppression therapies (i.e. estroprogestins and progestins) are generally used as first-line treatment to alleviate pain symptoms. Second-line options include other hormonal suppressants, such as gonadotropin-releasing hormone agonists and antagonists and, less commonly, danazol and aromatase inhibitors.


Compliance with ethical standards

Conflict of interest

The article was adapted from Drugs 2018;78(10):995–1012 [1] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.


The preparation of this review was not supported by any external funding.


  1. 1.
    Ferrero S, Barra F, Maggiore ULR. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018;78(10):995–1012.CrossRefGoogle Scholar
  2. 2.
    Kauppila A, Ronnberg L. Naproxen sodium in dysmenorrhea secondary to endometriosis. Obstet Gynecol. 1985;65(3):379–83.Google Scholar
  3. 3.
    Brown J, Crawford TJ, Allen C, et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017;1:CD004753.Google Scholar
  4. 4.
    Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–12.CrossRefGoogle Scholar
  5. 5.
    Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008;90(5):1583–8.CrossRefGoogle Scholar
  6. 6.
    Sesti F, Pietropolli A, Capozzolo T, et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III–IV: a randomized comparative trial. Fertil Steril. 2007;88(6):1541–7.CrossRefGoogle Scholar
  7. 7.
    Parazzini F, Di Cintio E, Chatenoud L, et al. Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Gruppo Italiano per lo Studio dell’Endometriosi. Eur J Obstet Gynecol Reprod Biol. 2000;88(1):11–4.CrossRefGoogle Scholar
  8. 8.
    Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010;93(7):2150–61.CrossRefGoogle Scholar
  9. 9.
    Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis—a pilot study. Contraception. 2009;79(1):29–34.CrossRefGoogle Scholar
  10. 10.
    Wong AY, Tang LC, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2010;50(3):273–9.CrossRefGoogle Scholar
  11. 11.
    Vercellini P, Bracco B, Mosconi P, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril. 2016;105(3):734–743 e3.CrossRefGoogle Scholar
  12. 12.
    Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2012;3:CD002122.Google Scholar
  13. 13.
    Telimaa S, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecol Endocrinol. 1987;1(4):363–71.CrossRefGoogle Scholar
  14. 14.
    Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21(1):248–56.CrossRefGoogle Scholar
  15. 15.
    Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–41.CrossRefGoogle Scholar
  16. 16.
    Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91(3):675–81.CrossRefGoogle Scholar
  17. 17.
    Cosson M, Querleu D, Donnez J, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril. 2002;77(4):684–92.CrossRefGoogle Scholar
  18. 18.
    Takaesu Y, Nishi H, Kojima J, et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J Obstet Gynaecol Res. 2016;42(9):1152–8.CrossRefGoogle Scholar
  19. 19.
    Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006;85(2):314–25.CrossRefGoogle Scholar
  20. 20.
    Lan S, Ling L, Jianhong Z, et al. Analysis of the levonorgestrel-releasing intrauterine system in women with endometriosis. J Int Med Res. 2013;41(3):548–58.CrossRefGoogle Scholar
  21. 21.
    Andres Mde P, Lopes LA, Baracat EC, et al. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015;292(3):523–9.CrossRefGoogle Scholar
  22. 22.
    Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005;20(3):789–93.CrossRefGoogle Scholar
  23. 23.
    Morotti M, Venturini PL, Biscaldi E, et al. Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017;213:4–10.CrossRefGoogle Scholar
  24. 24.
    Vercellini P, Somigliana E, Consonni D, et al. Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on pain during intercourse and patient satisfaction. Hum Reprod. 2012;27(12):3450–9.CrossRefGoogle Scholar
  25. 25.
    Vercellini P, Frattaruolo MP, Somigliana E, et al. Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life. Hum Reprod. 2013;28(5):1221–30.CrossRefGoogle Scholar
  26. 26.
    Morotti M, Remorgida V, Venturini PL, et al. Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. Eur J Obstet Gynecol Reprod Biol. 2014;183:178–82.CrossRefGoogle Scholar
  27. 27.
    + J, Yu Q, Zhang S, et al. Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study. J Womens Health (Larchmt). 2018;27(2):148–55.CrossRefGoogle Scholar
  28. 28.
    Agarwal SK, Hamrang C, Henzl MR, et al. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. J Reprod Med. 1997;42(7):413–23.Google Scholar
  29. 29.
    Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010;12:CD008475.Google Scholar
  30. 30.
    Abu Hashim H. Gonadotrophin-releasing hormone analogues and endometriosis: current strategies and new insights. Gynecol Endocrinol. 2012;28(4):314–21.CrossRefGoogle Scholar
  31. 31.
    Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40.CrossRefGoogle Scholar
  32. 32.
    Ferrero S, Venturini PL, Ragni N, et al. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs. 2009;69(8):943–52.CrossRefGoogle Scholar
  33. 33.
    Ferrero S, Venturini PL, Gillott DJ, et al. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reprod Biol Endocrinol. 2011;9:88.CrossRefGoogle Scholar
  34. 34.
    Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004;19(1):160–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations